June 2003

Mounting scientific evidence is pointing toward a nutrient-like compound called lignan, found in trace amounts in plant based diets as a powerful ally in the battle against breast cancer. Brevail is the first lignan-based product to address the maintenance of orderly cellular division in the preservation of healthy breast tissue.

Brevail, a new proactive breast health product, raises lignan concentrations in women to levels demonstrated in women with an extraordinary history of breast health.

Brevail was researched and developed after scientific research revealed that women who ingest plantbased diets, habitually high in lignans, exhibit an extraordinary history of breast health. Today’s modern diet, high in refined foods lack lignans and consequently women have exceedingly low levels of protective lignans in their body. After only 48 hours of Brevail supplementation women participating in a university based, oral dosing study achieved lignan concentrations in plasma and urine equivalent to a reference group of women with a well-established history of extraordinary breast health.

Increased lifetime exposure to estrogen is the most well-known cause of breast cancer. Brevail directly addresses the estrogen factor.

The most well-known cause of breast cancer is an increased lifetime exposure to estrogens. This fact flies in the face of the wide-held public perception that breast cancer is primarily a hereditary disease. Only 10% of breast cancers are attributed to direct genetic heredity, while an astounding 90% are attributed to dietary, lifestyle and unknown causes. Undue exposure to estrogens can both initiate and fuel breast cancers. Lignans are structurally similar to estrogens and gently buffer the more powerful hormone by competing and displacing estrogen on estrogen receptor sites.

Lignan Research, makers of Brevail, are championing the concept of the “estrogen window” a model depicting a women’s cumulative lifetime exposure to estrogen. Factors that increase estrogen exposure, such as late menopause, open your window and increase risk for breast problems. Factors that decrease estrogen exposure, such as pregnancy, close your window reducing risk. Brevail is designed to displace excessive or toxic estrogens addressing the leading cause for breast related problems. The effect is a narrowing of the estrogen window.

Hormonal Harmony: Brevail Trial Usage Program

One hundred women participated in an exclusive 3-month trial usage program with Brevail. Many of these women reported greater peace of mind and sense of well-being associated with Brevail usage. Additionally, to the pleasant surprise of the participants, many experienced relief from symptoms related to PMS, peri, pre, and post-menopausal discomforts. In the wake of reports citing negative consequences associated with estrogen replacement therapy including the potential for increased risk for breast cancer, Brevail has come as welcome news to these women.

A percentage of each sale of Brevail is donated to the Breast Cancer Prevention Foundation, a non-profit entity dedicated to the memory of Debra Demos-Palys, the late wife of company president Raymond Palys. Debra lost her battle to breast cancer at the age of 31, prompting Ray to join forces with Lignan Research in 2001.

Brevail is protected by patent pending technology developed to isolate, concentrate, purify and standardize lignans resulting in optimal absorption and metabolism of lignans in the body with just one small capsule daily.

Brevail is a two time, research and development grant award winner issued by the Washington Technology Center, University of Washington.

Brevail is offered in convenient, once-daily capsules in 30-day supply packs for a .99 suggested retail price, and will be available nationwide in select health, drug and grocery stores beginning in October, 2003. To learn more, visit www.brevail.com or call 888-503-8300.